Skip to content

Clinical Evaluation of Runfei Jianpi Decoction in Treating Chronic Cough in Children with Lung-Spleen Deficiency Syndrome

Clinical Evaluation of Runfei Jianpi Decoction in Treating Chronic Cough in Children with Lung-Spleen Deficiency Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001571
Enrollment
Unknown
Registered
2026-06-23
Start date
2025-06-18
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic cough of lung and spleen deficiency type in children

Interventions

control group:The control group received: oral Montelukast Sodium Chewable Tablets Children aged 3–5 years: 4mg per dose, chew once before b every night Children aged 6–12 years: 5mg per dose, chew on
treatment group:On the basis of montelukast sodium treatment in the control group, Rufeijianpi Decoction was added orally. I. Composion of Rufeijianpi Decoction 10g Angelica sinensis, 10g Paeonia lact
for infants with difficulty taking medicine, it can be taken in mu

Sponsors

Cangzhou Integrated Traditional Chinese and Western Medicine Hospital in Hebei Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Meet the Traditional Chinese Medicine diagnostic criteria for pediatric chronic cough (type of deficiency in both the lung and spleen); 2. Meet the Western medicine diagnostic criteria ftric chronic cough; 3. Aged 3 to 12 years; 4. The patient and guardian agree to participate in the observation and sign the informed consent form. Any inual who does not meet any of the above criteria will be excluded from the trial.

Exclusion criteria

Exclusion criteria: 1) Age 12 years; 2) Failure to meet the aforementioned diagnostic criteria for either Traditional Chinese Medicine (TCM) or Western medicine; 3) Presence of other diseases presenting with chronic cough as the predominant manifestation, such as bronchial asthma, bronchiolitis, foreign body aspiration, or gastroesophageal reflux; 4) Children with known hypersensitivity to any of the study medications; 5) Children currently receiving other pharmacological treatments for chronic cough; 6) Presence of developmental abnormalities, psychiatric disorders, or concurrent severe primary diseases involving other organ systems; 7) Inability to cooperate with the required examinations or treatment regimen. Any child meeting any of the above criteria will not be enrolled.

Design outcomes

Primary

MeasureTime frame
TCM Syndrome Score Reduction Rate;

Secondary

MeasureTime frame
Cough Symptom Score;LCQ;

Countries

China

Contacts

Public Contactchen limei

Cangzhou Integrated Traditional Chinese and Western Medicine Hospital in Hebei Province

chenlimeigenghao@163.com18031782928

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026